However, the shift to precision oncology involves therapy based more on molecular profiles and the context of an individual ...
Alicia Morgans, MD, MPH, discusses quality-of-life analyses from the ARANOTE and ARASENS trials and what they show about adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) in ...
Adding stereotactic body radiation therapy (SBRT) or surgery directed at every known metastasis to first-line systemic ...
Dr. Jason Mouabbi revisits the patient's Grade 2 hyperglycemia at week 6, when fasting glucose reaches 212 mg/dL.
Dr. Jason Mouabbi presents a 59-year-old postmenopausal woman with PIK3CA-mutated HR-positive/HER2-negative advanced breast ...
Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back ...
Dr. Jason Mouabbi discusses additional adverse events that require attention when managing patients with PIK3CA-mutated ...
VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively ...
Dr. Jason Mouabbi discusses the approach to managing treatment-related hyperglycemia while maintaining cancer treatment for ...
Dr. Jason Mouabbi discusses how available pathway-directed treatment approaches may be differentiated for patients with ...
Dr. Jason Mouabbi discusses strategies for assessing and managing the risk of treatment-related hyperglycemia before ...
However, applying a conventional age-based testing threshold would have substantially reduced the number of patients identified. Restricting testing to patients diagnosed before age 50 would have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results